Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kava

This article was originally published in The Tan Sheet

Executive Summary

Recent European AERs linking herbal to hepatotoxicity prompt NCCAM to suspend two sponsored trials underway at Duke University Jan. 7, pending guidance from FDA's investigation into the botanical's safety. Trial that began in July 2000 is comparing kava to Wyeth's Effexor XR (venelafaxine) in 124 generalized anxiety disorder patients. Second study, which began in July 2001, is exploring kava use in 48 patients with performance anxiety related to public speaking. A 1Jan. 16 Health Canada advisory urges consumers to avoid kava use while agency reviews safety, effectiveness data; New Zealand's Ministry of Health also is undertaking "limited" toxicological review. In Jan. 14 statement, AHPA advises consumers not to use kava if currently taking Rx or OTC drugs and to discontinue use if jaundice symptoms develop...

You may also be interested in...



Kava abroad

Health Canada is "requiring Canadian manufacturers, distributors and importers to stop the sale of kava-containing products" and requests these products be recalled from "all levels of the market," according to an 1Aug. 21 advisory. Announcement follows safety assessment of worldwide reports of liver toxicity associated with herbal (2"The Tan Sheet" Jan. 21, 2002, In Brief). Separately, Australia's Therapeutic Goods Administration initiated a voluntary kava recall Aug. 15 following the death of an Australian woman who took the herbal, likely with other botanicals, for four months...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel